scholarly journals Positive effects of auditory cue in locomotor pattern of people with Parkinson’s disease (off and on medication)

2014 ◽  
Vol 28 (4) ◽  
pp. 561-570 ◽  
Author(s):  
Natalia Madalena Rinaldi ◽  
Marcelo Pinto Pereira ◽  
Priscila Matias Formaggio ◽  
Luana Carolina Morais ◽  
Lilian Teresa Bucken Gobbi
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Muscular Activity ◽  
Experimental Conditions ◽  
Auditory Cues ◽  
Positive Effects ◽  
Locomotor Pattern ◽  
Healthy Elderly ◽  
Auditory Cue ◽  
Group 2

Gait disorders are identified in people with Parkinson’s disease. The aim of this study was to investigate the effect of auditory cues and medication on kinematic, kinetic and EMG parameters, during different gait phases of people with PD and healthy elderly. Thirty subjects distributed in two groups (Group 1, PD patients off and on medication; Group 2, healthy elderly) participated in this study and were instructed to walk in two experimental conditions: non-cued and cued. Therefore, kinematic, kinetic and electromyography analyses were utilized to investigate the locomotor pattern. Changes in locomotor pattern (greater muscular activity) with auditory cue were observed for PD patients. Regarding the medication, locomotor parameter improvement was observed after levodopa intake in association with the auditory cue. These results confirm the hypothesis about the external cues therapy that could be used as a complement to drug therapy to achieve improvement in the locomotor pattern of PD patients.

scholarly journals Relationship between Muscular Activity and Postural Control Changes after Proprioceptive Focal Stimulation (Equistasi®) in Middle-Moderate Parkinson’s Disease Patients: An Explorative Study

Sensors ◽  
2021 ◽  
Vol 21 (2) ◽  
pp. 560
Author(s):  
Fabiola Spolaor ◽  
Marco Romanato ◽  
Guiotto Annamaria ◽  
Antonella Peppe ◽  
Leila Bakdounes ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Postural Control ◽  
Quantitative Estimation ◽  
Force Plate ◽  
Muscular Activity ◽  
Rectus Femoris ◽  
Biceps Femoris ◽  
Eyes Open ◽  
Romberg Test

The aim of this study was to investigate the effects of Equistasi®, a wearable device, on the relationship between muscular activity and postural control changes in a sample of 25 Parkinson’s disease (PD) subjects. Gait analysis was carried out through a six-cameras stereophotogrammetric system synchronized with two force plates, an eight-channel surface electromyographic system, recording the activity of four muscles bilaterally: Rectus femoris, tibialis anterior (TA), biceps femoris, and gastrocnemius lateralis (GL). The peak of the envelope (PoE) and its occurrence within the gait cycle (position of the peak of the envelope, PPoE) were calculated. Frequency-domain posturographic parameters were extracted while standing still on a force plate in eyes open and closed conditions for 60 s. After the treatment with Equistasi®, the mid-low (0.5–0.75) Hz and mid-high (0.75–1 Hz) components associated with the vestibular and somatosensory systems, PoE and PPoE, displayed a shift toward the values registered on the controls. Furthermore, a correlation was found between changes in proprioception (power spectrum frequencies during the Romberg Test) and the activity of GL, BF (PoE), and TA (PPoE). Results of this study could provide a quantitative estimation of the effects of a neurorehabilitation device on the peripheral and central nervous system in PD.

scholarly journals The Cognition of Maximal Reach Distance in Parkinson’s Disease

2016 ◽  
Vol 2016 ◽  
pp. 1-8
Author(s):  
Satoru Otsuki ◽  
Masanori Nagaoka
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Rating Scale ◽  
Target Object ◽  
Clinical Findings ◽  
Reaching Movements ◽  
Spatial Distance ◽  
Distance Error ◽  
Healthy Elderly ◽  
Disease Rating

This study aimed to investigate whether the cognition of spatial distance in reaching movements was decreased in patients with Parkinson’s disease (PD) and whether this cognition was associated with various symptoms of PD. Estimated and actual maximal reaching distances were measured in three directions in PD patients and healthy elderly volunteers. Differences between estimated and actual measurements were compared within each group. In the PD patients, the associations between “error in cognition” of reaching distance and “clinical findings” were also examined. The results showed that no differences were observed in any values regardless of dominance of hand and severity of symptoms. The differences between the estimated and actual measurements were negatively deviated in the PD patients, indicating that they tended to underestimate reaching distance. “Error in cognition” of reaching distance correlated with the items of posture in the motor section of the Unified Parkinson’s Disease Rating Scale. This suggests that, in PD patients, postural deviation and postural instability might affect the cognition of the distance from a target object.

scholarly journals Apomorphine in the treatment of Parkinson's disease: a review

2018 ◽  
Vol 76 (12) ◽  
pp. 840-848 ◽  
Author(s):  
Renata Ramina Pessoa ◽  
Adriana Moro ◽  
Renato Puppi Munhoz ◽  
Hélio A.G. Teive ◽  
Andrew J. Lees
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Rescue Therapy ◽  
Continuous Process ◽  
Subcutaneous Administration ◽  
Historical Background ◽  
Infusion Therapy ◽  
Disease Treatment ◽  
Positive Effects

ABSTRACT Optimizing idiopathic Parkinson's disease treatment is a challenging, multifaceted and continuous process with direct impact on patients’ quality of life. The basic tenet of this task entails tailored therapy, allowing for optimal motor function with the fewest adverse effects. Apomorphine, a dopamine agonist used as rescue therapy for patients with motor fluctuations, with potential positive effects on nonmotor symptoms, is the only antiparkinsonian agent whose capacity to control motor symptoms is comparable to that of levodopa. Subcutaneous administration, either as an intermittent injection or as continuous infusion, appears to be the most effective and tolerable route. This review summarizes the historical background, structure, mechanism of action, indications, contraindications and side effects, compares apomorphine infusion therapy with other treatments, such as oral therapy, deep brain stimulation and continuous enteral infusion of levodopa/carbidopa gel, and gives practical instructions on how to initiate treatment.

scholarly journals Transcranial Direct Current Stimulation to Enhance Cognitive Impairment in Parkinson's Disease: A Systematic Review and Meta-Analysis

2020 ◽  
Vol 11 ◽  
Author(s):  
Diana M. A. Suarez-García ◽  
Johan S. Grisales-Cárdenas ◽  
Máximo Zimerman ◽  
Juan F. Cardona
Keyword(s):  
Systematic Review ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Direct Current ◽  
Cognitive Deficits ◽  
Transcranial Direct Current Stimulation ◽  
Meta Analysis ◽  
Direct Current Stimulation ◽  
Positive Effects ◽  
Cognitive Improvement

Cognitive deficits are increasingly being recognized as a common trait in Parkinson's disease (PD). Recently, transcranial direct current stimulation (tDCS) has been shown to exert positive effects as an adjunctive therapy on motor and non-motor symptoms in PD. This systematic review and meta-analysis aims to provide an overview of reported evidence on the efficacy of tDCS interventions in the treatment of cognitive impairments in PD. A systematic literature review was conducted to examine articles that were published in the past 10 years and that study the effects of tDCS on cognitive deficits in PD patients. The PubMed, Scopus and Scielo databases were searched. Eight tDCS studies involving 168 participants were included for the analysis. Our meta-analysis results showed that anodal tDCS (atDCS) had various levels or no evidence of effectiveness. In the pre-post stimulation analysis, a strong effect was reported for executive functions (pre-post: g = 1.51, Z = 2.41, p = 0.016); non-significant effects were reported for visuospatial skills (pre-post: g = 0.27, Z = 0.69, p = 0.490); attention (pre-post: g = 0.02, Z = 0.08, p = 0.934), memory (pre-post: g = 0.01, Z = 0.03, p = 0.972) and language (pre-post: g = 0.07, Z = 0.21, p = 0.832). However, in the pre-follow-up stimulation analysis, the duration of the effect was not clear. This study highlights the potential effectiveness of atDCS to improve cognitive performance in PD patients but failed to establish a cause-effect relationship between tDCS intervention and cognitive improvement in PD. Future directions and recommendations for methodological improvements are outlined.

scholarly journals Proactive and Integrated Management and Empowerment in Parkinson’s Disease: Designing a New Model of Care

2020 ◽  
Vol 2020 ◽  
pp. 1-11 ◽  
Author(s):  
Emma Tenison ◽  
Agnes Smink ◽  
Sabi Redwood ◽  
Sirwan Darweesh ◽  
Hazel Cottle ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
United Kingdom ◽  
The Netherlands ◽  
Integrated Management ◽  
Models Of Care ◽  
Model Of Care ◽  
New Model ◽  
Positive Effects ◽  
The United Kingdom

Parkinson’s disease is the second most common neurodegenerative condition after Alzheimer’s disease. The number of patients will rise dramatically due to ageing of the population and possibly also due to environmental issues. It is widely recognised that the current models of care for people with Parkinson’s disease or a form of atypical parkinsonism lack continuity, are reactive to problems rather than proactive, and do not adequately support individuals to self-manage. Integrated models of care have been developed for other chronic conditions, with a range of positive effects. A multidisciplinary team of professionals in the United Kingdom and the Netherlands, all with a long history of caring for patients with movement disorders, used knowledge of deficiencies with the current model of care, an understanding of integrated care in chronic disease and the process of logic modelling, to develop a novel approach to the care of patients with Parkinson’s disease. We propose a new model, termed PRIME Parkinson (Proactive and Integrated Management and Empowerment in Parkinson’s Disease), which is designed to manage problems proactively, deliver integrated, multidisciplinary care, and empower patients and their carers. It has five main components: (1) personalised care management, (2) education and empowerment of patients and carers, (3) empowerment of healthcare professionals, (4) a population health approach, and (5) support of the previous four components by patient- and professional-friendly technology. Having mapped the processes required for the success of this initiative, there is now a requirement to assess its effect on health-related and quality of life outcomes as well as determining its cost-effectiveness. In the next phase of the project, we will implement PRIME Parkinson in selected areas of the United Kingdom and the Netherlands.

Phytochemicals as future drugs for Parkinson’s disease: a comprehensive review

2016 ◽  
Vol 27 (6) ◽  
pp. 651-668 ◽  
Author(s):  
Zahra Shahpiri ◽  
Roodabeh Bahramsoltani ◽  
Mohammad Hosein Farzaei ◽  
Fatemeh Farzaei ◽  
Roja Rahimi
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Prostaglandin E ◽  
Pharmaceutical Drugs ◽  
Dopamine Depletion ◽  
Therapeutic Approaches ◽  
Positive Effects ◽  
Fatty Acid Amides ◽  
Therapeutic Benefits ◽  
Wide Range

AbstractParkinson’s disease (PD) is the second most common chronic neurodegenerative disease that affects motor skills and cognitive performance. The conventional therapeutic approaches for the management of PD are just able to alleviate symptoms. Exploring for achieving novel substances with therapeutic benefits in PD patients is the focus of a wide range of current investigations. The aim of the present study is to comprehensively review phytochemicals with protective or therapeutic activities in PD and focus on their neuropsychopharmacological mechanisms. Various subgroups of polyphenols (flavonoids, phenolic acids, stilbenes, and lignanes) and terpenes are the most abundant groups of phytochemicals with well-established antiparkinsonian effects. Other phytochemical categories, such as alkaloids, cinnamates, carbohydrates, amino acids, and fatty acid amides, also have some representatives with positive effects in PD. Phytochemicals perform their antiparkinsonian effect through several mechanisms of action, including suppressing apoptosis (via the reduction of Bax/Bcl-2, caspase-3, -8, and -9, and α-synuclein accumulation), decreasing dopaminergic neuronal loss and dopamine depletion, reducing the expression of proinflammatory cytokines (such as prostaglandin E2, interleukin-6, interleukin-1β, and nuclear factor-κB), and modulating nuclear and cellular inflammatory signaling, elevation of neurotrophic factors, and improvement of antioxidant status. Plant-derived natural products can be considered as future pharmaceutical drugs or adjuvant treatment with conventional therapeutic approaches to improve their efficacy and alleviate their psychological adverse effects in the management of PD. Well-designed clinical trials are mandatory to evaluate the protective and healing benefits of phytochemicals as promising future drugs in the management of neurodegenerative diseases.

Symmetry Matched Auditory Cues Improve Gait Steadiness in Most People with Parkinson's Disease but not in Healthy Older People

2015 ◽  
Vol 5 (1) ◽  
pp. 105-116 ◽  
Author(s):  
Matthew A.D. Brodie ◽  
Roger T. Dean ◽  
Tim R. Beijer ◽  
Colleen G. Canning ◽  
Stuart T. Smith ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Older People ◽  
Auditory Cues
Sign in / Sign up

Export Citation Format

Share Document